Multiple Sclerosis News

Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary progressive multiple sclerosis, according to a company press release.

An oral brain-penetrant therapeutic delayed the onset of confirmed disability progression compared with placebo in those with non-relapsing secondary progressive MS, according to results from a phase 3 study.

The FDA has cleared an investigational new drug application for a phase 1 clinical trial evaluating a universal, allogenic cell therapy platform intended to treat progressive MS.

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

Merz Therapeutics announced that it has acquired assets from Acorda Therapeutics Inc. in development to treat Parkinson’s disease and multiple sclerosis.

The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.

DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV administration in multiple sclerosis at 24 weeks, according to David Jones, senior medical director at Genentech.

DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve relapsing multiple sclerosis, Gabriel Pardo, MD, said in this Healio video from the American Academy of Neurology annual meeting.

DENVER — Efficacy of fumarates to treat multiple sclerosis was consistent across four racial and ethnic groups, particularly for Black, Hispanic and Asian persons, according to a poster at the American Academy of Neurology annual meeting.